Loading clinical trials...
Loading clinical trials...
This is an open label clinical trial of imatinib mesylate 800 mg po/day in a population of patients with unresectable, recurrent glioblastoma multiforme. Patients will be treated for up to 12 months
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis
NCT06039709 · Recurrent Glioblastoma, Glioblastoma Multiforme, and more
NCT05765812 · Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
NCT06814496 · Melanoma, Medullary Thyroid Cancer, and more
NCT06069726 · Recurrent Glioblastoma
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
Rio Grande
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions